Search
Now showing items 1-3 of 3
The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study
(Mosby Inc., 2021)
Background: Immunotherapy improves overall survival (OS) in the second and later lines of renal cell carcinoma (RCC) treatment. Recent studies have suggested that antibiotic (ATB) use either shortly before or after the ...
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database
(Future Medicine, 2021)
Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes ...
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish oncology group kidney cancer consortium (TKCC) study
(Springer, 2022)
Background Pan-immune-infammation value (PIV) is an easily accessible immune marker based on peripheral blood to
estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients ...
